Published in Nat Med on March 01, 1998
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci U S A (1999) 3.21
Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A (2001) 2.35
Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med (1999) 2.33
Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol (1999) 2.29
Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J Virol (2000) 2.26
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A (2000) 2.24
Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A (1999) 2.17
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci U S A (1998) 1.67
CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol (2003) 1.48
A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol (1999) 1.38
Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol (2005) 1.34
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol (2005) 1.30
Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol (1998) 1.28
The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV. Proc Natl Acad Sci U S A (2001) 1.28
CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32. J Virol (1998) 1.25
Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J Virol (2003) 1.24
Chemokines: understanding their role in T-lymphocyte biology. Biochem J (1998) 1.22
HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci U S A (2000) 1.19
Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J Virol (2001) 1.15
Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J Virol (2005) 1.13
Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5. J Virol (2001) 1.10
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J Virol (2002) 1.06
Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood (2006) 1.03
Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins. J Virol (1999) 1.03
A whole genome association study of mother-to-child transmission of HIV in Malawi. Genome Med (2010) 0.99
CCR5 haplotypes and mother-to-child HIV transmission in Malawi. PLoS One (2007) 0.99
Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis. Genes Immun (2006) 0.96
Host genetic determinants of human immunodeficiency virus infection and disease progression in children. Pediatr Res (2009) 0.96
Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics. Retrovirology (2012) 0.96
CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol (1999) 0.96
Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne. J Virol (1999) 0.95
Chemokine genes--beating the odds. Nat Med (1998) 0.94
APOBEC3G levels predict rates of progression to AIDS. Retrovirology (2007) 0.93
Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol (2000) 0.92
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
Chemokine receptors and chemokines in HIV infection. J Clin Immunol (1998) 0.91
Polymorphisms in eight host genes associated with control of HIV replication do not mediate elite control of viral replication in SIV-infected Indian rhesus macaques. Immunogenetics (2006) 0.90
Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. J Virol (1998) 0.88
Natural Immunity to HIV: a delicate balance between strength and control. Clin Dev Immunol (2012) 0.87
Haplotype structure and linkage disequilibrium in chemokine and chemokine receptor genes. Hum Genomics (2004) 0.87
RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection: results from a large scale single ethnic population. J Korean Med Sci (2007) 0.85
Tripartite molecular beacons. Nucleic Acids Res (2002) 0.84
Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol (2004) 0.83
CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects. J Virol (2007) 0.83
Host genes and infectious diseases. Emerg Infect Dis (1998) 0.83
Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication. J Virol (2002) 0.82
Polymorphisms of chemokine and chemokine receptor genes in idiopathic immune-mediated posterior segment uveitis. Mol Vis (2007) 0.82
Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics (2005) 0.82
Genetic effects on HIV disease progression. Nat Med (1998) 0.81
Genetic variation and HIV-associated neurologic disease. Adv Virus Res (2013) 0.81
Genetic correlates influencing immunopathogenesis of HIV infection. Indian J Med Res (2011) 0.80
Genotyping of the CCR5 chemokine receptor by isothermal NASBA amplification and differential probe hybridization. Clin Diagn Lab Immunol (1999) 0.80
Genetic factors for aids progression: Analyses of HIV-1 resistant genes in India and therapeutic potentials of novel catalytic RNA and DNA molecules. Indian J Clin Biochem (2002) 0.78
The role of chemokine receptors in HIV infection. Sex Transm Infect (1999) 0.77
CCR5 promoter haplotypes differentially influence CCR5 expression on natural killer and T cell subsets in ethnically divergent HIV-1 uninfected South African populations. Immunogenetics (2012) 0.77
Genetic diversity and linkage disequilibrium in the chemokine receptor CCR2-CCR5 region among individuals and populations. Cytokine (2013) 0.77
Characterisation of SNP haplotype structure in chemokine and chemokine receptor genes using CEPH pedigrees and statistical estimation. Hum Genomics (2004) 0.76
C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection. Appl Transl Genom (2013) 0.76
Epidemiologically linked transmission of HIV-1 illustrates the impact of host genetics on virological outcome. AIDS (2009) 0.76
The CD4 C868T Polymorphism and Its Correlation with HIV-1 Infection in a Chinese Population. AIDS Res Hum Retroviruses (2015) 0.75
Genetic diversity and prevalence of CCR2-CCR5 gene polymorphisms in the Omani population. Genet Mol Biol (2013) 0.75
CCR2, CCR5, and CXCL12 variation and HIV/AIDS in Papua New Guinea. Infect Genet Evol (2015) 0.75
CD192 gene variant and susceptibility to cervical cancer: a meta analysis. Int J Clin Exp Med (2015) 0.75
CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer. Clin Exp Med (2015) 0.75
Serial analysis of gene expression. Science (1995) 60.15
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Characterization of the yeast transcriptome. Cell (1997) 11.33
Complications of endoscopic biliary sphincterotomy. N Engl J Med (1996) 11.10
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 10.27
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28
A public database for gene expression in human cancers. Cancer Res (1999) 8.81
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol (2001) 8.64
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol (1993) 8.62
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med (1995) 8.23
PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell (2001) 7.95
Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med (1991) 7.83
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science (1996) 7.73
Robust perfect adaptation in bacterial chemotaxis through integral feedback control. Proc Natl Acad Sci U S A (2000) 7.67
Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology (1999) 7.32
14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 7.20
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med (1999) 7.04
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33
Analysis of human transcriptomes. Nat Genet (1999) 6.14
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc (2001) 5.94
Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest (1986) 5.90
The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A (2004) 5.87
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology (1992) 5.64
Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med (1996) 5.63
Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science (1989) 5.60
Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell (1998) 5.52
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med (1996) 5.35
A new classification for HIV-1. Nature (1998) 5.30
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation (2000) 5.09
Indium phosphide nanowires as building blocks for nanoscale electronic and optoelectronic devices. Nature (2001) 5.09
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
Ligand binding to integrins. J Biol Chem (2000) 4.94
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol (1993) 4.83
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med (1998) 4.77
A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science (1999) 4.75
In vivo evidence of structural brain asymmetry in musicians. Science (1995) 4.71
Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature (2000) 4.68
Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med (1996) 4.57
HTLV-III in the semen and blood of a healthy homosexual man. Science (1984) 4.53
Electrostatic interactions of S4 voltage sensor in Shaker K+ channel. Neuron (1995) 4.49
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res (1997) 4.40
VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest (2000) 4.36
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J (1986) 4.32
Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J Clin Virol (2004) 4.28
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med (1995) 4.28
Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med (2001) 4.27
Delay or probability discounting in a model of impulsive behavior: effect of alcohol. J Exp Anal Behav (1999) 4.23
Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol (1993) 4.22
A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest (1992) 4.21
Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med (1989) 4.20
Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet (2000) 4.17
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med (1996) 4.13
Rapid detection of herpes-simplex-virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis. Lancet (1990) 4.12
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science (1997) 4.07
Separation of human breast cancer cells from blood by differential dielectric affinity. Proc Natl Acad Sci U S A (1995) 4.00
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol (1993) 3.95
Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A (1985) 3.93
A quantum dot single-photon turnstile device. Science (2000) 3.89